Trial Profile
A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study Romiplostim in Children with Immune Thrombocytopenia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2019
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 10 Dec 2019 Updated results (data cut off: 27 March 2019) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 22 Jul 2018 New trial record
- 17 Jun 2018 Interim results (n=203) presented at the 23rd Congress of the European Haematology Association